Biogen claims their decision was simply "a reprioritization of resources." However, Karlawish explains how the decision to stop the study and sale of Adulhem was simply for profit.
Citation:
"Aduhelm was a mess — and it could happen again," STAT, J Karlawish, February 6, 2024.